Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Scleroderma, Localized 1Radiation Injuries 1Prostatic Neoplasms 1Popliteal Cyst 1Polycystic Ovary Syndrome 1Pneumonia 1Neurodermatitis 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lichen Planus 1Leukemia, Hairy Cell 1Leukemia 1Keratoacanthoma 1Keloid 1Hemangioma 1Head and Neck Neoplasms 1Granuloma Annulare 1Dermoid Cyst 1Dendritic Cell Sarcoma, Interdigitating 1Cicatrix, Hypertrophic 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 119fludarabine phosphate 97Cytarabine 86fludarabine 74Methotrexate 70Rituximab 68Busulfan 56Whole-Body Irradiation 48Filgrastim 48Tacrolimus 43Mycophenolic Acid 43Antilymphocyte Serum 40Etoposide 37Peripheral Blood Stem Cell Transplantation 36Granulocyte Colony-Stimulating Factor 35Melphalan 34Vincristine 33Alemtuzumab 33Cyclosporine 32Clofarabine 30Azacitidine 30Dexamethasone 29Imatinib Mesylate 26thymoglobulin 25Doxorubicin 23sargramostim 22Lenalidomide 22Methylprednisolone 20Stem Cell Transplantation 19Daunorubicin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia × Adrenal Cortex Hormones × Clear all
NCT01497496 2021-04-27

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
29 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡